Skip to content

Study · Measured the body's own peptide · 2001

1 result

Effects of Ninjin-to on levels of brain-gut peptides (motilin, vasoactive intestinal peptide, gastrin, and somatostatin) in human plasma.

Naito T, Itoh H, Nagano T, Takeyama M

Biological & pharmaceutical bulletin1 Feb 2001Cited by 16 (Europe PMC)

PMID11217092 (opens in a new tab)DOI10.1248/bpb.24.194 (opens in a new tab)PepBankPUB-11217092
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialOther

    In healthy subjects, a single oral dose of the Kampo medicine Ninjin-to did not change plasma VIP levels.

    In plain wordsIn healthy people, the herbal medicine Ninjin-to did not change the body's own VIP levels in blood.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma VIP level after Ninjin-to
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    the medicine did not alter the levels of VIP.
    1 context sentence
    Summary · context
    We examined the effects of Ninjin-to, a traditional Chinese (Kampo) medicine, on the levels of brain-gut peptides (motilin, vasoactive intestinal peptide (VIP), gastrin, and somatostatin) in plasma from healthy subjects.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.